Meridian Bioscience, Inc.

Cincinnati, OH 45244

Market Performance

NASDAQ: VIVO
Market Cap $631 Million
52 Week High $18.58
52 Week Low $10.75

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $100K
First Award Date 05/01/88
Most Recent Award Date 09/30/04

Key Personnel

Last Name Name Awards Contact
Nickol Allen D Nickol 3
Morrow Kenneth J Morrow 1

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 05/29/05

DESCRIPTION (provided by applicant): The overall goal of this proposed Phase I project is to determine scientific merit and feasibility of constructing highly specific recombinant single chain variable fragment (scFv) antibodies to Clostridium difficile toxin A and toxin B, and detect their presence for rapid, inexpensive, and sensitive diagnos...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 08/31/93

Mycoplasma hominis is becoming recognized a human pathogen. It can be detected in a variety of body sites and has an impact adult and pediatric populations. Mycoplasma pneumonias is estimated to be responsible for 12 million cases of tracheobronchitis and atypical pneumonia yearly. There are no commercially available direct antigen diagnostic t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/90 - 08/31/91

Mycoplasma hominis is becoming recognized a human pathogen. It can be detected in a variety of body sites and has an impact adult and pediatric populations. Mycoplasma pneumonias is estimated to be responsible for 12 million cases of tracheobronchitis and atypical pneumonia yearly. There are no commercially available direct antigen diagnostic t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/88 - 10/31/88

Mycoplasma hominis is becoming recognized as a human pathogen. It can be detected in a variety of body sites and has an impact in both adult and pediatric populations. Currently there is no diagnostic test available. M. hominis is difficult to cultivate and requires serological identification which is time consuming and costly. We propose to ...